Pralatrexate experience in peripheral T-cell lymphoma: a multicenter retrospective study from Turkey

dc.authoridMehmet Hilmi Doğu / 0000-0001-7237-2637en_US
dc.authorscopusidMehmet Hilmi Doğu / 55212747300
dc.authorwosidMehmet Hilmi Doğu / W-2255-2017
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorMerdin, Alparslan
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorEkinci, Ömer
dc.contributor.authorAlbayrak, Murat
dc.contributor.authorHacıoğlu, Sibel Kabukçu
dc.contributor.authorKaya, Ayşe
dc.contributor.authorDo?u, Mehmet Hilmi
dc.date.accessioned2021-09-14T08:12:16Z
dc.date.available2021-09-14T08:12:16Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractPurpose: Pralatrexate is a new generation antifolate treatment agent used for the treatment of relapsed or refractory peripheral T-cell lymphomas. This study aims to determine the general characteristics of the patients receiving pralatrexate therapy in Turkey, contributing to the literature on the effectiveness of pralatrexate therapy in peripheral T-cell lymphomas by determining the response levels of such patients to the therapy. The study also attempts to clinically examine the major side effects observed in patients during treatment with pralatrexate. Methods: The study included patients with peripheral T-cell lymphoma followed up in the hematology units of several hospitals in Turkey. Overall, 20 patients aged 18 and over were included in the study. Results: The median age at the time of diagnosis was 58.5 years. PTCL-NOS (Peripheral T-cell lymphoma, not otherwise specified) subtype was in 40% of patients, making the PTCL-NOS the most common subtype in the study. In general, most patients were diagnosed with disease at an advanced stage. Pralatrexate therapy was given to the patients at a median treatment line of 3.5. Pralatrexate dose reduction was required in only 3 patients (15%). Response to pralatrexate therapy with partial remission (PR) and above was observed in 11 (55%) of the patients. Conclusion: Pralatrexate seemed to be a promising novel treatment in relapsed refractory PTCL patients. However, patients receiving pralatrexate should be followed up carefully for skin reactions, mucosal side effects, thrombocytopenia and neutropenia.en_US
dc.identifier.citationDal, M. S., Merdin, A., Erkurt, M. A., Ekinci, Ö., Albayrak, M., Hacıoglu, S. K., Kaya, A., Dogu, M. H., Hindilerden, F., Merter, M., Aras, M. R., Caglıyan, G. A., & Cakar, M. K. (2021). Pralatrexate experience in peripheral T-cell lymphoma : A multicenter retrospective study from Turkey. 26(4), 1536–1539.en_US
dc.identifier.endpage1539en_US
dc.identifier.issn1107-0625en_US
dc.identifier.issue4en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1536en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2057
dc.identifier.volume26en_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorDoğu, Mehmet Hilmi
dc.language.isoenen_US
dc.publisherZerbinis Publicationsen_US
dc.relation.ispartofJournal of B.U.ON.en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMulticenteren_US
dc.subjectPeripheral T-cell Lymphomaen_US
dc.subjectPralatrexateen_US
dc.titlePralatrexate experience in peripheral T-cell lymphoma: a multicenter retrospective study from Turkeyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
152.pdf
Boyut:
861.42 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: